Innoviva

Innoviva Debt

The Debt of Innoviva (INVA) as of Nov 22, 2026 is 269.02 M USD. In the previous year, Debt was 451.10 M USD — a change of -40.36% (lower).

Debt

269.02 MUSD

YoY

-40.36%

Last updated:

In 2025, Innoviva's total debt was 269.02 M USD, a -40.36% change from the 451.10 M USD total debt recorded in the previous year.

The Innoviva Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
382.86 M USD
Jan 1, 2019
377.12 M USD
Jan 1, 2020
410.52 M USD
Jan 1, 2021
394.76 M USD
Jan 1, 2022
544.07 M USD
Jan 1, 2023
449.08 M USD
Jan 1, 2024
451.10 M USD
Jan 1, 2025
269.02 M USD
The Innoviva Debt history
YEARDebtYoY
269.02 MUSD-40.36%
451.10 MUSD+0.45%
449.08 MUSD-17.46%
544.07 MUSD+37.82%
394.76 MUSD-3.84%
410.52 MUSD+8.86%
377.12 MUSD-1.50%
382.86 MUSD-36.12%
599.36 MUSD-16.30%
716.09 MUSD-2.32%
733.13 MUSD+1.03%
725.64 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innoviva Stock analysis

What does Innoviva do? Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva is one of the most popular companies on Eulerpool.

Debt Details

Understanding Innoviva's Debt Structure

Innoviva's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Innoviva's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Innoviva’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Innoviva’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Innoviva stock

Debt of Innoviva is 269.02 M USD in 2025.

Debt of Innoviva changed from 451.10 M USD to 269.02 M USD, representing a -40.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Innoviva since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Innoviva historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Innoviva

All Key Metrics — Innoviva